Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
PHASE2CompletedINTERVENTIONAL
Enrollment
48
Participants
Timeline
Start Date
April 14, 2015
Primary Completion Date
June 1, 2022
Study Completion Date
November 1, 2024
Conditions
Squamous Cell Carcinoma of the Head and NeckSquamous Cell Carcinoma, Head and Neck
Interventions
DRUG
Mitomycin-C
DRUG
Pegfilgrastim
Trial Locations (1)
63110
Washington University School of Medicine, St Louis
All Listed Sponsors
lead
Washington University School of Medicine
OTHER
NCT02369458 - Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies | Biotech Hunter | Biotech Hunter